Antibody drug for Ebola advanced by HHS
This development will be carried out as a part of an agreement between the department's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals Inc.
“The world has experienced the worst Ebola epidemic in history; by rapidly developing therapeutics and vaccines with nimble technologies, we may save lives and bring future outbreaks under control more quickly,” Biomedical Advanced Research and Development Authority Director Robin Robinson said. “Regeneron’s technology facilitated the discovery and development of this monoclonal antibody therapeutic candidate in real time in just nine months as compared to the normal development cycle of several years, and the technology may have potential applications in future public health responses.”
The monoclonal antibodies that will be pursued for this treatment were generated by Regeneron utilizing their VelocImmune and VelicuGene technologies. With this contract in place the company will be able to manufacture the candidate as it goes through the development and clinical trial processes and will support the filing of an investigational new drug application with the U.S. Food and Drug Administration (FDA).